David Rausher, MD
Gastroenterology · Decatur, GANPI 1588653976
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,047 of the $7,094 with a category attached, or 71.1%. 28 manufacturers reported payments, led by Pfizer at 25.3% of the total. Reporting peaked in 2023 at $2,367 and has fallen 66.7% since, to $789 in 2025.
Across 267 payments — averaging $26.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$2K
- AbbVie$1K
- Braintree Laboratories, Inc.$596
- Takeda Pharmaceuticals U.S.A., Inc.$594
- Intercept Pharmaceuticals, Inc.$372
- Regeneron Healthcare Solutions, Inc.$355
- plus $2K from 22 others
Across 249 payments — averaging $3623.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$154K
- Braintree Laboratories, Inc.$153K
- Janssen Research & Development, LLC$95K
- Bristol Myers Squibb$94K
- GSK$77K
- Takeda Pharmaceuticals U.S.A., Inc.$53K
- plus $277K from 13 others
What the payments were for
- Consulting fees$1,50021%
- Food & beverage$5,04771%
- Education$3164%
- Gifts$2313%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 19 | $1,797 |
| AbbVie(2 entities) | 53 | $1,077 |
| Braintree Laboratories, Inc. | 35 | $596 |
| Takeda Pharmaceuticals U.S.A., Inc. | 29 | $594 |
| Intercept Pharmaceuticals, Inc. | 18 | $372 |
| Regeneron Healthcare Solutions, Inc. | 13 | $355 |
| Madrigal Pharmaceuticals | 8 | $246 |
| Nestle Healthcare Nutrition Inc. | 9 | $226 |
| Ferring Pharmaceuticals Inc. | 15 | $218 |
| Johnson & Johnson | 8 | $213 |
| Sanofi | 7 | $204 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $172 |
| Pentax Of America, Inc. | 4 | $140 |
| QOL Medical, LLC | 4 | $134 |
| Ardelyx, Inc. | 5 | $111 |
| Lilly USA, LLC | 4 | $100 |
| Amgen | 4 | $89 |
| Gilead | 4 | $80 |
| Aimmune Therapeutics, Inc. | 2 | $77 |
| Bristol Myers Squibb | 3 | $65 |
| Ipsen Biopharmaceuticals, Inc | 2 | $49 |
| Novo Nordisk | 2 | $42 |
| Organon | 2 | $34 |
| Merck | 2 | $27 |
| Fresenius Kabi USA, LLC | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
| Medline Industries LP | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VELSIPITY$1,500
How this compares
$7,094 in reported general payments places this provider in the 65th percentile of 492 gastroenterology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpclusaSofosbuvir/Velpatasvir | 11 | $340,665 |
| XifaxanRifaximin | 11 | $35,586 |
| LinzessLinaclotide | 16 | $21,413 |
| Mesalamine | 20 | $16,609 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 43 | $7,346 |
| Azathioprine | 56 | $2,634 |
| Balsalazide Disodium | 11 | $1,564 |
| Pantoprazole Sodium | 140 | $1,539 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 23 | $1,494 |
| Tenofovir Disoproxil Fumarate | 14 | $831 |
| Famotidine | 82 | $827 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 21 | $430 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 26 | $429 |
| Nadolol | 14 | $313 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 16 | $286 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadEpclusa | $80 | $340,66511 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $172 | $35,58611 claims |
| AbbVieLinzess | $1,077 | $21,41316 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $218 | $7,34643 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 492 gastroenterology providers in Georgia.
Other gastroenterology in Decatur
- Nitin GuptaAtlanta$1.1M
- Cynthia RudertAtlanta$720K
- Douglas WolfAtlanta$668K
- Kavita KongaraAtlanta$492K
- Girish AnandAtlanta$425K
- Satish RaoAugusta$335K
- Roshan ShresthaAtlanta$317K
- Hetal KarsanAtlanta$314K
- Aja McCutchenWinder$310K
- Bruce SalzbergSuwanee$275K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.